Purpose Of Review: Allergen immunotherapy has been shown to be an effective treatment for respiratory allergies and Hymenoptera venom allergy. However, concern regarding its potential to cause anaphylaxis may limit its use. This review aims to assess whether anaphylaxis is still a worry when administering subcutaneous (SCIT) and sublingual immunotherapy (SLIT).
Recent Findings: Retrospective surveillance surveys and one ongoing North American prospective study have helped to characterize the incidence and risk factors for fatal and nonfatal systemic reactions to SCIT. The latest rate of very severe, World Allergy Organization grade 4, systemic reactions was similar to the previously reported rates of near-fatal reactions, that is, 1 in 1 million injections. Regarding SLIT, no fatalities have been reported. Case reports of anaphylaxis in clinical practice and in some clinical trials have been described; however, given the number of doses administered daily throughout the world, the number is very small.
Summary: Identification of possible risk factors and the introduction of safety guidelines and practice parameters have enabled the reduction in immunotherapy related systemic reactions. However, it is important that clinicians remain vigilant when administering immunotherapy and should be prepared to provide emergency treatment if required.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1097/ACI.0000000000000075 | DOI Listing |
Intensive Care Med Exp
January 2025
Department of Emergency Medicine in Linköping, and Department of Biomedical and Clinical Sciences, Linköping University, 582 25, Linköping, Sweden.
Background: This study aimed to investigate whether changes in capillary refill (CR) time precede macrovascular signs of deterioration in a human model of blood loss shock. The study was conducted at the Department of Emergency Medicine in Linköping, Sweden, and involved 42 healthy volunteers aged 18-45. Participants were randomized into two provocations of applied lower body negative pressure (LBNP): a stepwise escalation protocol and a direct application protocol, to simulate gradual and acute blood loss.
View Article and Find Full Text PDFMed Mycol Case Rep
March 2025
Department of Dermatology, Tenri Hospital, 200 Mishima, Tenri, Nara, 632-8552, Japan.
We report a case of kerion celsi caused by in a teenage male judo athlete, presenting with a lesion in the occipital region. Following the initiation of systemic antifungal therapy, the patient developed a dermatophytid reaction, necessitating differentiation from a drug eruption. Direct microscopy of the affected area confirmed the presence of fungal elements, and histopathological examination revealed endothrix invasion, supporting the continuation of treatment.
View Article and Find Full Text PDFTher Adv Endocrinol Metab
November 2024
Aurealis Therapeutics, Microkatu 1, Kuopio 70210, Finland.
Background: Diabetic foot ulcer (DFU) is a common and highly morbid complication of diabetes with high unmet medical needs. AUP1602-C, a topical four-in-one gene therapy medicinal product (GTMP), consisting of a strain that produces fibroblast growth factor-2, interleukin-4, and colony-stimulating factor-1, is a promising novel treatment for DFU.
Objectives: The aim of this first-in-human study was to investigate whether AUP1602-C is safe and effective in improving wound healing and quality of life (QoL) in patients with non-healing DFU (nhDFU), and to determine the recommended phase II dose.
Arthritis Res Ther
January 2025
Department of Rheumatology and Immunology, West China Hospital, Sichuan University, Chengdu, 610041, China.
Background: Rheumatoid arthritis (RA) is a systemic disease that primarily manifests as chronic synovitis of the symmetric small joints. Despite the availability of various targeted drugs for RA, these treatments are limited by adverse reactions, warranting new treatment approaches. Suberosin (SBR), isolated from Plumbago zeylanica-a medicinal plant traditionally used to treat RA in Asia-possesses notable biological activities.
View Article and Find Full Text PDFmSystems
January 2025
School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Unlabelled: Despite the prevalence and severity of enterococcal bacteremia (EcB), the mechanisms underlying systemic host responses to the disease remain unclear. Here, we present an extensive study that profiles molecular differences in plasma from EcB patients using an unbiased multi-omics approach. We performed shotgun proteomics and metabolomics on 105 plasma samples, including those from EcB patients and healthy volunteers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!